Adjuvant treatment of stage IB NSCLC. The problem of stage subset heterogeneity

Royce Calhoun, David Jablons, Derick H Lau, David R Gandara

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


While 5-year survival rates in patients with stage IB non-small-cell lung cancer (NSCLC) are historically modest (40% to 67%), adjuvant chemotherapy trials including this subgroup have shown little evidence of chemotherapeutic benefit. This article reviews the available data regarding adjuvant chemotherapy following surgically resected stage IB NSCLC, framed within the context of present and future proposed definitions of this diagnosis. The discussion addresses limitations of the current staging system and how this contributes to the mixed results seen with adjuvant treatment. In addition, the authors consider current treatment options for stage IB NSCLC and review planned clinical trials for stage I disease designed to exploit new pharmacogenomic findings.

Original languageEnglish (US)
Pages (from-to)511-516
Number of pages6
Issue number5
StatePublished - Apr 30 2008

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adjuvant treatment of stage IB NSCLC. The problem of stage subset heterogeneity'. Together they form a unique fingerprint.

Cite this